1. Scrip

Padcev Positioned For Urothelial Cancer Expansion

US sBLA Planned Soon

 
• By Ian Haydock

First-in-class ADC set for expanded use on the back of additional data, but analysts see first-line setting as probably the main growth driver.

urothelial cancer
Padcev Moving Ahead In Urothelial Cancer Settings • Source: Shutterstock

Seagen Inc. and partner Astellas Pharma, Inc. have presented additional clinical results for Padcev (enfortumab vedotin) confirming significant improvements in both overall and progression-free survival versus chemotherapy in previously treated urothelial cancer patients, and setting up the first-in-class antibody-drug conjugate (ADC) for further approval progress in this setting.

Primary results from the global, 600-patient Phase III EV-301 trial were presented at the virtual American Society of Clinical Oncology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By Mandy Jackson

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.